Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4645]

ASH 2017: Sustained benefit with Ibrutinib in r/r MCL

ASH 2017: Sustained benefit with Ibrutinib in r/r MCL

SABCS 2017: PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations

SABCS 2017: PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA...

First line combination therapy improves progression-free survival in advanced lung cancer

First line combination therapy improves progression-free survival in advanced lung cancer

SABCS 2017: Phase III EMBRACA trial meets primary PFS endpoint

SABCS 2017: Phase III EMBRACA trial meets primary PFS endpoint

SABCS 2017: Older women with HR-positive breast cancer may receive similar benefit from CDK 4/6 inhibitors as younger women

SABCS 2017: Older women with HR-positive breast cancer may receive similar benefit from CDK 4/6 inhibitors as...

SABCS 2017: Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer

SABCS 2017: Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast...

SABCS 2017: Two years of extended anastrazole therapy as effective as five

SABCS 2017: Two years of extended anastrazole therapy as effective as five

SABCS 2017: Contrast-enhanced digital mammography comparable to breast MRI after therapy or chemo

SABCS 2017: Contrast-enhanced digital mammography comparable to breast MRI after therapy or chemo

Breakthroughs in understanding the genetic basis of aggressive prostate cancer

Breakthroughs in understanding the genetic basis of aggressive prostate cancer

SABCS 2017: Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer

SABCS 2017: Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer

More from ecancer